Regulation News: Breaking Regulation News, Comments and Articles. - Page: 3

06:14 EDT 22nd September 2014 | BioPortfolio

Regulation News - Page: 3RSS

Read the latest Regulation News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Regulation.

Search or Follow Our Regulation - Page: 3 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Regulation - Page: 3 News.

Showing "regulation regulatory" News Articles 51 to 75 of 7,200+

Thursday 18th September 2014

InspireMD to Host Conference Call and Webinar and to Discuss Recently Released Results of CGuard™ CARENET Trial on September 24th

BOSTON, Sept. 18, 2014 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems ("EPS"), will host a live webinar and Q&A to discuss the positive results of its recent CARENET (CARotid Embolic protection study using microNET) Trial for its CGuard™ Embolic Protection System (EPS) which were announced at the Transcatheter ...

Ventas Prices Cdn$400 Million of 3.00% Senior Notes Due 2019 and Cdn$250 Million of 4.125% Senior Notes Due 2024

Ventas, Inc. (NYSE: VTR) (“Ventas” or the “Company”) said today that it has priced a private offering in Canada of Cdn$400 million of 3.00% Senior Notes, Series A due 2019 and Cdn$250 million of 4.125% Senior Notes, Series B due 2024 (collectively, the “Notes”). The sale of the Notes is expected to close on September 24, 2014. The Note...

Peel Hunt upbeat on ECO Animal Health's antiobiotic; starts coverage

ECO Animal Health's (LON:EAH) Aivlosin antibiotic for pigs and poultry is driving growth at the company and has significant advantages over existing products, says broker Peel Hunt, which has started covering the stock. It rates the shares a 'buy' wi...

Nurix, Inc. Names Arthur T. Sands, M.D., Ph.D., Chief Executive Officer

Nurix Expands Leadership Team with Appointment of Pierre Beaurang, Ph.D., as Vice President, Business and Corporate Development Nurix, Inc., a leader in discovering and developing therapies that modulate the ubiquitin proteasome system (UPS), announced today the appointment of Arthur T. Sands, M.D., Ph.D., as chief executive officer. Dr. Sands s...

Evariant Announces Appointment of Kristin Hambelton as Chief Marketing Officer

FARMINGTON, Conn., Sept. 18, 2014 /PRNewswire/ -- Evariant, a leader in leveraging big data, specifically targeted relevant analytics and relationship management tools and methods to achieve healthcare transformation, today announced that Kristin Hambelton has been named chief marketing officer (CMO) for the company. As CMO, Hambelton will be responsible for leading marketing and inside sales at E...

Minnesota Dental Association Announces 2014-15 Officers and Honors Senator Julie Rosen

MINNEAPOLIS, Sept. 18, 2014 /PRNewswire-USNewswire/ -- The Minnesota Dental Association recently held its annual House of Delegates meeting at the Hilton Airport Hotel in Bloomington where new officers were elected. The newly-elected 2014-2015 officers include: Dr. Dan Rose, as president; Dr. Peter Cannon as president-elect; Dr. Kevin Dens as first vice-president; Dr. R. David Resch as second vice...

Gastroenterologists Present United Front on Capitol Hill

BETHESDA, Md., Sept. 18, 2014 /PRNewswire-USNewswire/ -- Physician members of the American Gastroenterological Association (AGA) will travel to Capitol Hill tomorrow to send a clear message to Congress that impending changes in health care will jeopardize both the science and practice of gastroenterology. The inability of Congress to address key issues of concern to our members will directly ...

Dallen Medical Announces First in Man Use of Its Compressyn™ Staple for Small Bone Fixation

Dallen Medical, Inc., an innovator in bone fixation and repair, today announced the first human use of its Compressyn™ Staple, the only rigid compression fixation technology that delivers continual, dynamic compression for small bone fixation. The first procedure was a treatment for an arthritic foot, where the Compressyn staple was used ...

Salix Secures Additional Intellectual Property Relating to Rifaximin

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that Cipla Limited has granted Salix exclusive rights under certain patent applications in the “Rifaximin Complexes” patent family controlled by Cipla. The grant is on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa. Additionally, Salix and Cipla have expanded th...

Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar

LONDON, September 18, 2014 /PRNewswire/ -- Pharma IQ, after huge demand from their audience, has updated the incredibly successful Serialisation Countdown calendar to cover the years 2014 - 2018 inclusive. The interactive PDF, available at pharmaserialisation.com shows the serialisation requirements around the globe and the month in which they will be coming into force. For companies dealing wi...

ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board

NORTHVALE, N.J., Sept. 18, 2014 /PRNewswire/ -- ADM Tronics Unlimited, Inc. (OTCQB: ADMT) has appointed Gianluca DeNovi, Ph.D. to its corporate Advisory Board for business development. Dr. DeNovi is an instructor at the Harvard Medical School and Visiting Professor at the University Campus Bio-Medico of Rome.  He received his Masters degree in Electronics Engineering and his Ph.D. i...

Trends In Regulatory Convergence And Global Life Sciences Compliance To Be Key Topics Of Discussion At Maetrics' Booth #527 At Regulatory Affairs Professionals Conference (RAPS)

PHILADELPHIA, Sept. 18, 2014 /PRNewswire/ -- Maetrics, a global life sciences consulting firm will be attending the upcoming RAPS conference in Austin, Texas during its exhibition days, September 29th and 30th.  Representatives from the Leadership and Solutions Delivery teams will be available to speak on current trends in regulatory convergence and global life sciences compliance at Mae...

Synergy Pharmaceuticals Reaches Halfway Mark for Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has reached the halfway mark for total enrollment in the second pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation (CIC). The trial is currently being conducted at 180 sites and has randomized over 675 CIC patients. This is the second of two ongoi...

Pharma and Omics Journals to Address Global Challenges during Open Access Week

OMICS Group International invites researchers, authors and academicians across the globe to participate in the ‘Open Access Week’ by actively contributing their research outcome as articles to OMICS Group Pharma and Omics Journals from 20-26th October, 2014. (PRWEB) September 18, 2014 OMICS Group International invites researchers, authors and academicians across the globe to participate in th...

Insigniam Consultant Named to Editorial Advisory Board for Applied Clinical Trials Magazine

Ira Katz brings more than 30 years in pharmaceuticals to the magazine's editorial advisory board. Philadelphia, PA (PRWEB) September 18, 2014 International management consulting firm Insigniam announced that its consultant, Ira Katz, has been named to the editorial advisory board for Applied Clinical Trials. Applied Clinical Trials is a global, peer-reviewed publication with coverage that fea...

Prosensa announces commencement of re-dosing of drisapersen in North America in patients with Duchenne muscular dystrophy.

LEIDEN, The Netherlands – September 17, 2014 – Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that a comprehensive program of re-dosing has commenced, with the first patients now re-dosed in the United States. All dosing in the drisapersen clinical program had been p...

SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer

SAN DIEGO, Sept. 18, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on patient enrollment and dosing of PEGPH20 in SWOG's ongoing Phase 1b/2 clinical trial (S1313). The trial is designed to evaluate Halozyme's investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) ...

MEI Pharma To Present At BioCentury's NewsMakers Conference

SAN DIEGO, Sept. 18, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at BioCentury's NewsMakers in the Biotech Industry conference on Friday, September 26, 2014 at 8:30 a.m. Eastern time from the Millennium...

Cubist Announces Continued Global Expansion with Opening of International Headquarters in Zurich

Company reinforces its commitment to global public health with more investment in antibiotic R&D than any company worldwide With resistant bacterial infections resulting in an estimated 25,000 deaths in the European Union and 23,000 deaths in the United States annually, the issues of rising antibiotic resistance and the lack of treatment ...

How stress tears us apart: Enzyme attacks synaptic molecule, leading to cognitive impairment

Why is it that when people are too stressed they are often grouchy, grumpy, nasty, distracted or forgetful? Researchers have just highlighted a fundamental synaptic mechanism that explains the relationship between chronic stress and the loss of socia...

Minomic Launches US Pilot Study of MiStat(TM) Novel Prostate Cancer Screening Technology

SYDNEY, Sept. 18, 2014 /PRNewswire/ -- Australian biomarker discovery company Minomic International Ltd will today launch an important US trial of its MiStat™ prostate cancer screening test, planning to achieve US Food and Drug Administration (FDA) regulatory approval upon completion. Minomic's proprietary MiStat™ technology is a screening assay capable of identifying the prese...

Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development

NEW YORK, Sept. 18, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Mr. Christopher W. James to the position of  Senior Director of Clinical Development. During his extensive career in Clinical Research, Mr. James has established and led successful glob...

Galapagos reports high participation rate in long term extension study with GLPG0634 in RA patients

Mechelen, Belgium; 18 September 2014 - Galapagos NV (Euronext: GLPG) announced today that more than 100 patients have completed the six month Darwin 1 and 2 studies with GLPG0634 in rheumatoid arthritis and entered Darwin 3, the long term extension study.  With the support of their treating physicians, over 90% of the patients who participated in Darwin 1 and Darwin 2 have chosen to partici...

Molecular regulation of cell fate in cerebral ischemia: role of the inflammasome and connected pathways

Whitehouse Labs Announces Package Testing Laboratory Expansion

Facility upgrade brings an additional 4,000 square feet of dedicated research and development space New York, NY (PRWEB) September 18, 2014 Whitehouse Laboratories is pleased to announce that it has completed negotiations with Salem Realty Group and has acquired an additional 4,000 square feet of dedicated research and development space within the Salem Executive Complex adjacent to its current p...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks